Edgewise Therapeutics Inc (EWTX)
21.37
+0.14
(+0.66%)
USD |
NASDAQ |
May 08, 12:31
Edgewise Therapeutics Enterprise Value: 1.658B for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2024 | 1.658B |
| May 06, 2024 | 1.575B |
| May 03, 2024 | 1.499B |
| May 02, 2024 | 1.478B |
| May 01, 2024 | 1.452B |
| April 30, 2024 | 1.352B |
| April 29, 2024 | 1.269B |
| April 26, 2024 | 1.187B |
| April 25, 2024 | 1.166B |
| April 24, 2024 | 1.182B |
| April 23, 2024 | 1.139B |
| April 22, 2024 | 1.086B |
| April 19, 2024 | 1.100B |
| April 18, 2024 | 1.120B |
| April 17, 2024 | 1.139B |
| April 16, 2024 | 1.230B |
| April 15, 2024 | 1.216B |
| April 12, 2024 | 1.206B |
| April 11, 2024 | 1.217B |
| April 10, 2024 | 1.165B |
| April 09, 2024 | 1.189B |
| April 08, 2024 | 1.253B |
| April 05, 2024 | 1.261B |
| April 04, 2024 | 1.220B |
| April 03, 2024 | 1.404B |
| Date | Value |
|---|---|
| April 02, 2024 | 1.327B |
| April 01, 2024 | 1.359B |
| March 28, 2024 | 1.380B |
| March 27, 2024 | 1.354B |
| March 26, 2024 | 1.278B |
| March 25, 2024 | 1.171B |
| March 22, 2024 | 1.195B |
| March 21, 2024 | 1.254B |
| March 20, 2024 | 1.243B |
| March 19, 2024 | 1.189B |
| March 18, 2024 | 1.128B |
| March 15, 2024 | 1.257B |
| March 14, 2024 | 1.271B |
| March 13, 2024 | 1.303B |
| March 12, 2024 | 1.332B |
| March 11, 2024 | 1.241B |
| March 08, 2024 | 1.279B |
| March 07, 2024 | 1.333B |
| March 06, 2024 | 1.264B |
| March 05, 2024 | 1.262B |
| March 04, 2024 | 1.264B |
| March 01, 2024 | 1.236B |
| February 29, 2024 | 1.202B |
| February 28, 2024 | 1.232B |
| February 27, 2024 | 1.251B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
15.26M
Minimum
May 25 2022
1.658B
Maximum
May 07 2024
452.34M
Average
289.23M
Median
Enterprise Value Benchmarks
| Sarepta Therapeutics Inc | 12.71B |
| PTC Therapeutics Inc | 1.838B |
| Fate Therapeutics Inc | 69.87M |
| Viking Therapeutics Inc | 7.813B |
| Regenxbio Inc | 556.15M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -30.14M |
| Total Expenses (Quarterly) | 33.86M |
| EPS Diluted (Quarterly) | -0.47 |
| Earnings Yield | -7.39% |